List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Chemotherapy Induced Peripheral Neuropathy - Overview
Chemotherapy Induced Peripheral Neuropathy - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Chemotherapy Induced Peripheral Neuropathy - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Chemotherapy Induced Peripheral Neuropathy - Companies Involved in Therapeutics Development
Achelios Therapeutics Inc
Apexian Pharmaceuticals Inc
Aphios Corp
Aptinyx Inc
Asahi Kasei Pharma Corp
Celgene Corp
DermaXon LLC
Disarm Therapeutics Inc
Emerald Bioscience Inc
Exodos Life Sciences Limited Partnership
Immune Pharmaceuticals Inc
Insys Therapeutics Inc
KannaLife Sciences Inc
Kineta Inc
Kyorin Pharmaceutical Co Ltd
MAKScientific LLC
Metys Pharmaceuticals AG
Mundipharma International Ltd
NeurExo Sciences LLC
Osmol Therapeutucs Inc
PeriphaGen Inc
PharmatrophiX Inc
PledPharma AB
Sensei Biotherapeutics Inc
Sonnet BioTherapeutics Inc
Sova Pharmaceuticals Inc
Stealth BioTherapeutics Corp
Trevena Inc
WEX Pharmaceuticals Inc
Winsantor Inc
YD Life Science Co
Chemotherapy Induced Peripheral Neuropathy - Drug Profiles
(amitriptyline + ketamine hydrochloride) - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ACY-1083 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
AM-1710 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
APH-1503 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
APX-2009 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
APX-3330 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
atexakin alfa - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Biologics for Chemotherapy Induced Peripheral Neuropathy - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
BR-297 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
cannabidiol - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Drugs for Chemotherapy Induced Peripheral Neuropathy and Neurology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
DX-0332 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ibudilast - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
KCP-400 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ketoprofen - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
KLS-13019 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
LM-11A31BHS - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
MP-101 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
MR-309 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
NB-2111 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
NRX-2922 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
PAN-811 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
PGN-503 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
pirenzepine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
PP-095 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ricolinostat - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SBT-20 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules for Pain - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Block Nav 1.8 for Chemotherapy Induced Peripheral Neuropathy - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit SARM1 for Neurology and Glaucoma - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SV-250 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Tetrodotoxin - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
thrombomodulin alfa - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
TRV-045 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
YD-308 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Chemotherapy Induced Peripheral Neuropathy - Dormant Projects
Chemotherapy Induced Peripheral Neuropathy - Discontinued Products
Chemotherapy Induced Peripheral Neuropathy - Product Development Milestones
Featured News & Press Releases
Oct 22, 2019: Disarm Therapeutics reports preclinical data demonstrating small molecule SARM1 inhibitors preserve both axonal structure and function in vitro and in vivo
Sep 04, 2019: Disarm Therapeutics announces first subject enrolled in EPIPHANY natural history study of chemotherapy-induced peripheral neuropathy (CIPN)
Jun 27, 2019: Kannalife to present breakthrough CIPN study findings on the comparison of KLS-13019 to CBD at 29th Annual International Cannabinoid Research Society Conference
May 21, 2019: Kannalife publishes new research on chemotherapy-induced peripheral neuropathy
Jan 17, 2019: PledPharma presents PledOx’s phase III program at the Gastrointestinal (GI) Cancers Symposium
Dec 26, 2018: Solasia initiates phase III program for PledOx in Japan
Sep 28, 2018: Study drug for the PledOx global phase III program delivered
Jun 13, 2018: Japanese Medical Agency (PMDA) supports the expansion of the Phase III program for PledOx to include Japanese patients
Apr 16, 2018: Apexian Pharmaceuticals to present two poster sessions at AACR meeting in Chicago - April 14-18, 2018
Feb 08, 2018: Delayed delivery of study drug for the PledOx phase III program - top-line results still expected during 2020, in line with previous communication
Nov 17, 2017: PledPharma’s Phase IIb study with PledOx (PLIANT) published in Acta Oncologica
Nov 16, 2017: PledPharma initiates Phase III studies with PledOx before year end 2017
Sep 27, 2017: National Cancer Institute selects Apexian Pharmaceuticals to participate in the Small Business Innovation Research (SBIR) Initiative program
Aug 24, 2017: PledPharma establishes a Scientific Advisory Board for the continued clinical development of PledOx
Aug 02, 2017: Nemus Bioscience Announces Presentation of NB2111 Analgesic and Anti-Addiction Data at NIH-Sponsored Cannabinoid Conference
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Table 1: Number of Products under Development for Chemotherapy Induced Peripheral Neuropathy, H2 2019
Table 2: Number of Products under Development by Companies, H2 2019
Table 3: Number of Products under Development by Companies, H2 2019 (Contd..1), H2 2019
Table 4: Number of Products under Development by Universities/Institutes, H2 2019
Table 5: Products under Development by Companies, H2 2019
Table 6: Products under Development by Companies, H2 2019 (Contd..1), H2 2019
Table 7: Products under Development by Universities/Institutes, H2 2019
Table 8: Number of Products by Stage and Target, H2 2019
Table 9: Number of Products by Stage and Mechanism of Action, H2 2019
Table 10: Number of Products by Stage and Route of Administration, H2 2019
Table 11: Number of Products by Stage and Molecule Type, H2 2019
Table 12: Chemotherapy Induced Peripheral Neuropathy - Pipeline by Achelios Therapeutics Inc, H2 2019
Table 13: Chemotherapy Induced Peripheral Neuropathy - Pipeline by Apexian Pharmaceuticals Inc, H2 2019
Table 14: Chemotherapy Induced Peripheral Neuropathy - Pipeline by Aphios Corp, H2 2019
Table 15: Chemotherapy Induced Peripheral Neuropathy - Pipeline by Aptinyx Inc, H2 2019
Table 16: Chemotherapy Induced Peripheral Neuropathy - Pipeline by Asahi Kasei Pharma Corp, H2 2019
Table 17: Chemotherapy Induced Peripheral Neuropathy - Pipeline by Celgene Corp, H2 2019
Table 18: Chemotherapy Induced Peripheral Neuropathy - Pipeline by DermaXon LLC, H2 2019
Table 19: Chemotherapy Induced Peripheral Neuropathy - Pipeline by Disarm Therapeutics Inc, H2 2019
Table 20: Chemotherapy Induced Peripheral Neuropathy - Pipeline by Emerald Bioscience Inc, H2 2019
Table 21: Chemotherapy Induced Peripheral Neuropathy - Pipeline by Exodos Life Sciences Limited Partnership, H2 2019
Table 22: Chemotherapy Induced Peripheral Neuropathy - Pipeline by Immune Pharmaceuticals Inc, H2 2019
Table 23: Chemotherapy Induced Peripheral Neuropathy - Pipeline by Insys Therapeutics Inc, H2 2019
Table 24: Chemotherapy Induced Peripheral Neuropathy - Pipeline by KannaLife Sciences Inc, H2 2019
Table 25: Chemotherapy Induced Peripheral Neuropathy - Pipeline by Kineta Inc, H2 2019
Table 26: Chemotherapy Induced Peripheral Neuropathy - Pipeline by Kyorin Pharmaceutical Co Ltd, H2 2019
Table 27: Chemotherapy Induced Peripheral Neuropathy - Pipeline by MAKScientific LLC, H2 2019
Table 28: Chemotherapy Induced Peripheral Neuropathy - Pipeline by Metys Pharmaceuticals AG, H2 2019
Table 29: Chemotherapy Induced Peripheral Neuropathy - Pipeline by Mundipharma International Ltd, H2 2019
Table 30: Chemotherapy Induced Peripheral Neuropathy - Pipeline by NeurExo Sciences LLC, H2 2019
Table 31: Chemotherapy Induced Peripheral Neuropathy - Pipeline by Osmol Therapeutucs Inc, H2 2019
Table 32: Chemotherapy Induced Peripheral Neuropathy - Pipeline by PeriphaGen Inc, H2 2019
Table 33: Chemotherapy Induced Peripheral Neuropathy - Pipeline by PharmatrophiX Inc, H2 2019
Table 34: Chemotherapy Induced Peripheral Neuropathy - Pipeline by PledPharma AB, H2 2019
Table 35: Chemotherapy Induced Peripheral Neuropathy - Pipeline by Sensei Biotherapeutics Inc, H2 2019
Table 36: Chemotherapy Induced Peripheral Neuropathy - Pipeline by Sonnet BioTherapeutics Inc, H2 2019
Table 37: Chemotherapy Induced Peripheral Neuropathy - Pipeline by Sova Pharmaceuticals Inc, H2 2019
Table 38: Chemotherapy Induced Peripheral Neuropathy - Pipeline by Stealth BioTherapeutics Corp, H2 2019
Table 39: Chemotherapy Induced Peripheral Neuropathy - Pipeline by Trevena Inc, H2 2019
Table 40: Chemotherapy Induced Peripheral Neuropathy - Pipeline by WEX Pharmaceuticals Inc, H2 2019
Table 41: Chemotherapy Induced Peripheral Neuropathy - Pipeline by Winsantor Inc, H2 2019
Table 42: Chemotherapy Induced Peripheral Neuropathy - Pipeline by YD Life Science Co, H2 2019
Table 43: Chemotherapy Induced Peripheral Neuropathy - Dormant Projects, H2 2019
Table 44: Chemotherapy Induced Peripheral Neuropathy - Dormant Projects, H2 2019 (Contd..1), H2 2019
Table 45: Chemotherapy Induced Peripheral Neuropathy - Discontinued Products, H2 2019

List of Figures
Figure 1: Number of Products under Development for Chemotherapy Induced Peripheral Neuropathy, H2 2019
Figure 2: Number of Products under Development by Companies, H2 2019
Figure 3: Number of Products under Development by Universities/Institutes, H2 2019
Figure 4: Number of Products by Top 10 Targets, H2 2019
Figure 5: Number of Products by Stage and Top 10 Targets, H2 2019
Figure 6: Number of Products by Top 10 Mechanism of Actions, H2 2019
Figure 7: Number of Products by Stage and Top 10 Mechanism of Actions, H2 2019
Figure 8: Number of Products by Top 10 Routes of Administration, H2 2019
Figure 9: Number of Products by Stage and Top 10 Routes of Administration, H2 2019
Figure 10: Number of Products by Molecule Types, H2 2019
Figure 11: Number of Products by Stage and Molecule Types, H2 2019

Companies Mentioned
• Achelios Therapeutics Inc
• Apexian Pharmaceuticals Inc
• Aphios Corp
• Aptinyx Inc
• Asahi Kasei Pharma Corp
• Celgene Corp
• DermaXon LLC
• Disarm Therapeutics Inc
• Emerald Bioscience Inc
• Exodos Life Sciences Limited Partnership
• Immune Pharmaceuticals Inc
• Insys Therapeutics Inc
• KannaLife Sciences Inc
• Kineta Inc
• Kyorin Pharmaceutical Co Ltd
• MAKScientific LLC
• Metys Pharmaceuticals AG
• Mundipharma International Ltd
• NeurExo Sciences LLC
• Osmol Therapeutucs Inc
• PeriphaGen Inc
• PharmatrophiX Inc
• PledPharma AB
• Sensei Biotherapeutics Inc
• Sonnet BioTherapeutics Inc
• Sova Pharmaceuticals Inc
• Stealth BioTherapeutics Corp
• Trevena Inc
• WEX Pharmaceuticals Inc
• Winsantor Inc
• YD Life Science Co